The Novavax Covid-19 vaccine, which goes by the Scrabble-friendly trade name “Nuvaxovid,” has been authorized as a two-dose primary series given three weeks. or roughly only two Scaramuccis apart.

LONDON -- American biotechnology company Novavax announced Monday that its experimental COVID-19 vaccine was more than 90% effective against symptomatic disease in late-stage clinical trials ...

Earlier this month, the U.S. Department of Health and Human Services (HHS) announced that the Biden administration had secured 3.2 million doses of Novavax’s COVID-19 vaccine, which will be made ...

Novavax Inc. said Thursday Jan. 28, 2021 that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well ...

Vaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico.

The U.S. Food and Drug Administration on Friday authorized an updated version of the protein-based Novavax COVID-19 vaccine for use in people 12 and up. Doses could be available by the end of next ...

Novavax’s latecomer Covid-19 vaccine gets U.S. authorization. The vaccine was authorized as a primary immunization series for adults, rather than a booster, which may limit its market at first.

Novavax is moving closer to being approved in the U.S. as the newest inoculation against COVID-19, raising hopes that its more established technology will win over vaccine skeptics and increase ...

Novavax Inc. said Thursday Jan. 28, 2021 that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well ...

The FDA authorized an updated version of the protein-based Novavax COVID-19 vaccine for use in people 12 and up. Doses could be available by next week.

The FDA authorized an updated version of the protein-based Novavax COVID-19 vaccine for use in people 12 and up. Doses could be available by next week.